AirSculpt Technologies shared its Q3 2026 earnings, showing an 8.7% drop in sales to $31.9 million.

Nov 6, 2026, 9:18 AM ETResultsRead the original at Benzinga

Bad for AIRS

AirSculpt's sales and adjusted EBITDA fell, and its full-year sales expectation came down. Loan refinancing and GLP-1 procedures offer support, but they do not undo the declines in sales, profit, and leads.

AIRS · AirSculpt Technologies

AI read · Bad for AIRS

The AI's read

Fewer Google clicks cut leads, and each lead cost more. Problems at several clinics added pressure on sales and profit. Conversion has steadied, and GLP-1 procedures made up nearly 10% of cases. The loan extension gives AirSculpt more room, but these positives do not erase the lower sales expectation.

Get alerts for AIRS

Follow AirSculpt Technologies (AIRS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AIRS

Free on the App Store and Google Play, or on the web.